Immune Response Modulation by Vitamin D: Role in Systemic Lupus Erythematosus by Mirentxu Iruretagoyena et al.
MINI REVIEW
published: 12 October 2015
doi: 10.3389/fimmu.2015.00513
Edited by:
Sergio Quezada,
University College London Cancer
Institute, UK
Reviewed by:
Abdelhadi Saoudi,
Institut National de Recherche
Scientifique, France
David Cameron Wraith,
University of Bristol, UK
*Correspondence:
Mirentxu Iruretagoyena and
Paula Isabel Burgos,
Departamento de Inmunología
Clínica y Reumatología,
Facultad de Medicina, Pontificia
Universidad Catolica de Chile,
Marcoleta 350, Santiago 8330033,
Chile
mitureta@med.puc.cl;
pburgos@med.puc.cl
Specialty section:
This article was submitted to
Immunological Tolerance, a section of
the journal Frontiers in Immunology
Received: 01 July 2015
Accepted: 21 September 2015
Published: 12 October 2015
Citation:
Iruretagoyena M, Hirigoyen D,
Naves R and Burgos PI (2015)
Immune response modulation by
vitamin D: role in systemic lupus
erythematosus.
Front. Immunol. 6:513.
doi: 10.3389/fimmu.2015.00513
Immune response modulation by
vitamin D: role in systemic lupus
erythematosus
Mirentxu Iruretagoyena1*, Daniela Hirigoyen1, Rodrigo Naves2 and Paula Isabel Burgos1*
1 Departamento de Inmunología Clínica y Reumatología, Facultad de Medicina, Pontificia Universidad Católica de Chile,
Santiago, Chile, 2 Programa de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina Universidad de Chile,
Santiago, Chile
Vitamin D plays key roles as a natural immune modulator and has been implicated in
the pathophysiology of autoimmune diseases, including systemic lupus erythematosus
(SLE). This review presents a summary and analysis of the recent literature regarding
immunoregulatory effects of vitamin D as well as its importance in SLE development,
clinical severity, and possible effects of supplementation in disease treatment.
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Introduction
1,25-Dihydroxyvitamin D is a steroid hormone, primarily known for its important role in calcium
homeostasis (1). The description that several human tissues and cells express the vitamin D receptor
(VDR), allows a growing interest in extra-skeletal functions of this vitamin (2). It is now clear that
vitamin D plays an essential role in a variety of physiological conditions and that its deficiency is
associated with chronic illnesses, including disorders of calcium metabolism, cancers, cardiovascu-
lar, and of our special interest, autoimmune diseases: applying to both development and severity of
disease (3, 4). In this review, currently available data are summarized to give an overview of the role
vitamin D plays on cells of the immune system and the regulation of inflammatory responses, with
special emphasis on the role it has in the treatment of systemic lupus erythematosus (SLE).
Vitamin D comes from three potential sources: (i) it can be made in the skin from exposure
to sunlight, (ii) nutritional sources, and (iii) supplements (5, 6). In humans, vitamin D is mainly
synthesized in the skin after exposure to UVB whereas only a minor part (<10%) is derived from
dietary sources (7). There are two major forms of vitamin D: ergocalciferol (vitamin D2) that is
obtained from UV irradiation and cholecalciferol (vitamin D3) that is synthesized in the skin and is
present in oil-rich fish (8). Both vitamin D2 and vitamin D3 are used for food fortification (such as
dairy products) and in vitamin D supplements. Vitamin D levels depend on season, reaching their
lowest levels after winter and their maximum at the end of summer.
Vitamin D (D represents D2, or D3, or both) after it is ingested is incorporated into chylomicrons,
which are absorbed into the lymphatic system and enter the venous blood. In the skin, cholecalciferol
is synthesized from 7-dehydrocholesterol when exposed to UVB. Vitamin D that comes from the
skin or diet is biologically inert and requires its first hydroxylation in the liver by the vitamin D-25-
hydroxylase (25-OHase) to 25(OH)D, which represents the main circulating vitamin D metabolite
and is themost reliable parameter to define human vitaminD status (9). However, 25(OH)D requires
a further hydroxylation in the kidneys by the 25(OH)D-1-OHase (CYP27B1) to form the biologically
active form of vitamin D 1,25(OH)2D (9). This process is under strict control of parathyroid
hormone and the phosphaturic hormone fibroblast growth factor 23 (FGF-23). High levels of
vitaminD inhibit CYP27B1 and stimulate CYP24A1, an enzyme thatmetabolizes vitaminD into the
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inactive, water-soluble form, calcitroic acid, which is then excreted
into the bile. Circulating levels of 1,25(OH)2D are determined by
renal CYP27B1 activity. Interestingly, other cell types, including
immune cells, also express CYP27B1, and these cells are able to
convert the inactive hormone into the active form, in an autocrine
or paracrine manner. This process lacks feedback mechanisms (as
the ones described for kidney cells), and allows the production of
high local concentrations of vitamin D.
1,25(OH)2D interacts with VDR, which is present in several
human tissues and cells (1, 9). VDR is a member of transcription
factor family, characterized by a highly conserved DNA-binding
domain and a structurally conserved ligand-binding domain, and
it acts as a modulator of gene transcription (1). 1,25(OH)2D may
be responsible for regulating up to 200 genes that may facilitate
many of the pleiotropic health benefits that have been reported
for vitamin D (1, 5, 6). Ligand binding initiates a conformational
change that increases the receptor’s affinity to the retinoidX recep-
tor (RXR), then VDR-vitamin D complex forms heterodimers
with RXR and the complex binds to vitamin D response elements
on DNA and recruits a number of nuclear co-activator and co-
repressor proteins (10). The gene encoding VDR is located on
chromosome 12q13.11, contains 9 exons and 8 introns and several
single nucleotide polymorphisms (SNPs) have been described.
Mainly four, including BsmI and ApaI (both in intron 8), Fok1
and TaqI (located in the start codon), have been intensively
studied (11).
Serum 25(OH)D is considered as the most accurate marker
for vitamin D. Vitamin D deficiency has been recently recom-
mended by the Institute of Medicine (IOM) as a vitamin D of
<20 ng/mL, whereas vitamin D insufficiency has been defined
as levels between 21 and 29 ng/mL (12, 13). This classifica-
tion is based on vitamin D effects on bone and mineral home-
ostasis. The serum concentration of the active 1,25(OH)2D is
approximately 1000-fold lower and far below the effective con-
centration described in in vitro studies. Most in vitro studies
use more that 100-fold higher concentrations of 1,25(OH)2D
than found in serum, to obtain an effect. It has been suggested
that the level of circulating 1,25(OH)2D is too low to affect
immune responses in vivo, and that sufficient levels are obtained
by local conversion of 25(OH)D3 to 1,25(OH)2D. Other impor-
tant players influencing the bioavailable levels of vitamin D are
the vitamin D-binding protein (DBP) and albumin. 25(OH)D3
and 1,25(OH)2D circulate bound to DBP (85–90%) and albumin
(10–15%)with<1% in their free form (14). Studies inmice lacking
DBP have shown that DBP acts as a vitamin D reservoir by pro-
tecting 25(OH)D3 and 1,25(OH)2D from degradation and renal
secretion (15).
The major cause of vitamin D deficiency is inadequate expo-
sure to sunlight (6, 16). There is an inverse association of serum
vitamin D and body mass index (BMI), and thus, obesity is
also associated with vitamin D deficiency (17). Patients with fat
malabsorption syndromes and bariatric patients are often unable
to absorb the fat-soluble vitamin D, and patients with nephritic
syndrome lose 25(OH)D bound to vitamin DBP in the urine (18).
Patients on a wide variety of medications, chronic granuloma-
forming disorders, some lymphomas, and primary hyperparathy-
roidism have a high risk for vitamin D deficiency (19).
Supplementation with vitamin D in the general population has
shown fracture prevention, suggested benefit in cardiovascular
health, colorectal cancer prevention and reduction of proteinuria
in patients with chronic kidney disease (20, 21). However, a pos-
sible harm of vitamin D supplementation has been documented
in some studies: a meta-analysis showed that supplementation
with calcium and vitamin D could be associated with the modest
increase in the risk of cardiovascular events, especially myocardial
infarction (22). Currently, no international consensus is avail-
able on the optimal vitamin D supplementation level; recom-
mendations differ in many countries and medical societies. The
Endocrine Society considers a supplementation of 10,000 IU daily
to be safe, the IOM considers 4000 IU/day and the European Food
and SafetyAuthority recommends staying below 4000 IU/day. The
most common forms of vitamin D for supplementation are chole-
calciferol (vitamin D3) and ergocalciferol (vitamin D2), although
administration of calcitriol is limited because of potential side
effects. A recent work by Souberbielle et al. (23) has shown that
a target level of at least 30–40 ng/mL of vitamin D serum level was
recommended in adult patients with risk of fractures, falls, can-
cers, and autoimmune and cardiovascular disease. Serum levels
higher than 150 ng/mL may cause acute vitamin D intoxication
with hypercalcemia, hypercalciuria, and calcifications in different
organs.
Vitamin D and the Immune Response
Several studies suggest that calcitriol can enhance the innate
immune response, whereas it can inhibit the adaptive immune
response (24). Early evidence suggesting that vitamin D could act
as stimulant for innate immunity comes from reports about tuber-
culosis treatment with cod liver oil (25). It enhances chemotaxis
and phagocytic capabilities of innate immune cells and activates
the transcription of antimicrobial peptides, such as defensin B
and cathelicidin (26). Low 25(OH)D concentrations have been
linked to increased mortality caused by severe infections in end-
stage renal disease patients, and have been associated with upper
respiratory tract infections and allergic asthma.
In particular, dendritic cells (DCs) are important targets for
the immunomodulatory effects of vitamin D. DCs are profes-
sional antigen presenting cells (APCs) that play an important role
in maintaining peripheral tolerance by preventing self-reactive
T cells from causing autoimmune damage. Through their unique
ability to efficiently capture antigens and trigger the adaptive
immune response, DCs are critical for the defense against infec-
tious agents and tumors (27). In addition to activating immune
responses, DCs also play a central role in peripheral T cell tol-
erance, by inducing T cell anergy or unresponsiveness to self-
antigens (28). Calcitriol and its analogs are able to suppress DC
differentiation (29) and maturation in vitro. Likewise, vitamin D,
by inhibiting the maturation of DCs, can make them tolerogenic
(30–32). It has been shown that DC can produce 1,25(OH)2D
from 25(OH)D in vitro, and respond to this through the VDR in
an autocrine fashion. Since DCs are central to the maintenance
of self-tolerance, it is possible that a deficiency in vitamin D
could have consequences on their maturation and function and
consequently on the risk of developing autoimmune diseases as
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well as disease severity. In addition, vitamin D exerts effects that
oppose the effect of IL-4 on MHC class II antigen expression
in human monocytes and specifically modulates human mono-
cyte phenotype and function by altering HLA-DR expression and
antigen presentation, leaving lytic function intact (33).
T and B cells express VDR and are important target cells of
calcitriol immune regulation. Vitamin D can suppress cellular and
humoral immunity in several animal models as it plays an impor-
tant role in regulating proliferation, differentiation of activated
B cell, and immunoglobulin production (34, 35). In vitro studies
have shown that vitamin D inhibits IL-17 synthesis, inhibiting
Th17 differentiation and increases the quantity of CD4+ CD25+
T regulatory cells, which produce IL-10 and amplifies a Th1–Tr1
switch (36) (Figure 1).
Vitamin D and Autoimmune Diseases
Several studies have now reported vitamin D insufficiencies
in various autoimmune disorders. In addition to observational
studies, numerous randomized trials have addressed the question
whether vitaminD levels are associatedwith the risk of developing
autoimmunity and whether development and disease progression
can be influenced by vitamin D supplementation. In the following
section, we have summarized the latest results associating vita-
min D insufficiency and vitamin D supplementation in SLE. If
causal, these associations might be of great importance for public
health.
Vitamin D and Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic multisystem autoim-
mune disease that can manifest with a diverse array of clini-
cal symptoms and which is characterized by the production of
autoantibodies directed against nuclear antigens (37). Systemic
injury may arise as a consequence of inflammation caused by
direct autoantibody-mediated tissue injury and the deposition of
complement-fixing immune complexes (ICs) (38). IC-mediated
inflammation has been shown to damage multiple organs, such
as skin, joints, kidneys, brain, and blood vessels. Cellular and
molecular mechanisms underlying this autoimmune disease are
not completely understood. Currently, there is no cure for SLE,
and treatments, such as long-term corticosteroids, may contribute
to further health risks.
In SLE animal models, it has been shown a relation between
vitamin D and disease manifestations. Lemire et al. (39) showed
that in the MRL/1 SLE mouse model, supplementation with
25(OH)D for 18weeks reduced dermatologic lesions, proteinuria,
and anti-DNA antibodies. Instead, Vaisberg et al. (40) described
opposing results in the NZB/W mice that were injected with
different concentrations of vitamin D. Treatment with cholecal-
ciferol led to a worsening of the histopathological findings in the
kidneys of female F1 NZB/Wmice. In vitro studies of SLE-derived
PBMCs have shown that when these cells are incubated with cal-
citriol, reduced cellular proliferation and anti-DNA antibodies are
observed (41). Also, in vitro vitamin D reduced the expression of
CD40, MHC class II, CD86, and inhibited the activation of APCs
FIGURE 1 | Vitamin D effects on the innate and adaptive immune response. Vitamin D has been shown to enhance chemotaxis, antimicrobial peptides, and
macrophage differentiation. It can also inhibit DCs maturation, Th1 and Th17 differentiation, and promotes immunoregulatory functions of Treg cells.
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TABLE 1 | Clinical studies of the effects of vitamin D supplementation in patients with systemic lupus erythematosus.
Author, year,
country
Sample
size
Subjects Intervention (type, dose, duration) Study results
Petri, 2013,
USA (64)
1006 SLE Oral cholecalciferol 50,000 IU weekly+ 200U
calcium/vitamin D twice daily
A 20-U increase in the 25(OH)D level was associated with
decrease of 0.22 of SELENA-SLEDAI and 2% decrease in
urine protein-to-creatinine ratio
Abou-Raya, 2013,
Egypt (71)
267 SLE Oral cholecalciferol 2000 IU/day or placebo for
12months
69% suboptimal VitD
39% deficient VitD
Lower VitD correlates with higher disease activity
Change in 25(OH)D after 12months is associated with
improvement in inflammatory-hemostatic markers
Ruiz-Irastorza, 2010,
Spain (70)
80 SLE Oral cholecalciferol 600–800 IU day for 24months Beneficial effect on fatigue, no significant correlations were
seen in SLEDAI or SDI values
Lima, 2015, Brazil 60 juvSLE Oral cholecalciferol 50,000 IU/week or placebo for
24weeks
Beneficial effect on fatigue and decrease disease activity
Aranow, 2015,
USA (73)
57 SLE Oral cholecalciferol 2000 or 4000 IU for 12weeks No changes in IFN signature in vitamin D deficient SLE
patients
Andreoli, 2015,
Italy (72)
34 SLE Oral cholecalciferol Intensive regimen significantly raise vitamin D serum levels
Intensive R: 300,000 IU initial bolus followed by
50,000 IU monthly (850,000 annually)
No significant differences in disease activity, or SLE
serology were found
Standard R: 25,000 IU monthly (300,000 annually) for
12months and then switched in the second year
Piantoni, 2015,
Italy (74)
34 SLE Oral cholecalciferol Vitamin D treatment promotes regulatory T cells
proliferation and production of Th2 cytokinesIntensive R: 300,000 IU initial bolus followed by
50,000 IU monthly (850,000 annually)
Standard R: 25,000 IU monthly (300,000 annually) for
12months and then switched in the second year
Terrier, 2012,
France (75)
20 SLE Oral cholecalciferol Increase of naive CD4 T cells
100,000 IU/week during 4weeks Increase in regulatory T cells
100,000 IU/month for 6months Decrease Th1 and Th17 cells
Decrease memory B cells
Decrease anti-DNA antibodies
derived from SLE patients (42). Ben-Zvi et al. (43) showed that
vitamin D treatment reduced the expression of IFNα-regulated
genes in healthy and SLE patients-derived DCs in response to
factors in activating SLE plasma.
Levels ofmicroRNA (miRNA)-146a in PBMCs correlate signif-
icantly with disease activity in SLE patients and urinary expres-
sion correlates with estimated glomerular filtration rate (44).
Recent studies have shown that after treatment with vitamin D,
miRNA-146a levels of SLE patients tend to decrease (44).
Association studies with VDR polymorphism and SLE suscep-
tibility have been performed in different populations with contro-
versial results (45–47). A meta-analysis study, including a total of
11 case-control studies (8 from Asian, 2 European, 1 Latino pop-
ulation), of 1683 patients and 1883 healthy individuals revealed
associations between the VDR polymorphisms and SLE (48).
These findings show that the BsmI and FokI polymorphisms are
associated with increased risk of SLE, especially in the Asian
population. Limitations to the study are the low representation of
European and Latino populations.
Hypovitaminosis D is highly prevalent in SLE as a result of
avoidance of sunshine, renal insufficiency, and the use of medica-
tions, such as glucocorticoids, anticonvulsants, and antimalarials,
which alter the metabolism of vitamin D, vitamin D-binding pro-
tein levels or downregulate the functions of the VDR (49, 50). Sev-
eral studies have reported suboptimal vitamin D levels in patients
with SLE, whose prevalence described varies between 36.8% and
75% in the different populations studied (49, 51–54). Low levels
of vitamin D have been correlated with disease activity, and are
associated with osteoporosis, fatigue, and certain cardiovascular
risk factors in SLE patients (49, 55). The wide variation reported
can be related to age, ethnicity, geographic location, and season at
the time of the study.
Vitamin D Deficiency and Disease Activity
There are several cross-sectional studies examining the relation-
ship between low vitamin D levels and SLE activity. It has been
shown that vitamin D deficiency has an association with disease
activity and some clinical manifestations, but there are discrep-
ancies between the different populations studied. No associations
between adolescent dietary vitamin D intake and adult SLE risk
were observed in a prospective cohort of women (56, 57). Mok
et al. reported in a cross-sectional study with 290 Chinese patients
with SLE, that vitamin D deficiency was inversely correlated
with disease activity, measured by SLEDAI scores (58), and in
another study, they reported associations with anti-dsDNA levels
(59). In addition, Lertratanakul et al. showed that lower baseline
vitamin D levels are associated with higher cardiovascular risk
factors and more active SLE (60). Besides, SLE patients with
higher vitamin D levels were less likely to have hypertension and
hyperlipidemia. A recent study that evaluated 129 Indian patients
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with SLE found a negative correlation of vitamin D levels with
disease activity, anti-dsDNA, plasma IFN-α, and IFN-α gene
expression (61). Baseline vitamin D levels were not associated
with relapse-free survival rate (62). In Australian patients, Yap
et al. showed that low vitamin D is associated with higher disease
activity, and an increase in vitamin Dwas associated with reduced
disease activity over time (50). Other studies have shown that
vitamin D deficiency is associated with a higher B cell activation,
more frequent leukopenia or renal involvement with proteinuria,
and higher titers of anti-DNA (51, 63–66). By contrast, others
studies have reported no association between vitamin D and
fatigue, SLEDAI score or cytokine profile (67–69).
Overall, both in vitro and in vivo studies of vitamin D effects in
SLE provide immunological basis for potential beneficial effects
of vitamin D in this disease. Despite all this overwhelming evi-
dence favoring the use of vitamin D in SLE, to date, vitamin D
supplementation is not the standard of care for patients with SLE.
Interventional studies have been reported (see Table 1), with the
purpose of changing clinical outcomes; however, results are still
not conclusive.
Ruiz-Irastorza et al. showed no significant correlations with
SLE clinical activity, evaluating SLEDAI or SDI values, and sug-
gested that increasing vitamin D levels may have a beneficial
effect on fatigue (70). Petri et al. studied a prospective cohort of
1006 patients receiving supplementation with 50,000 IU weekly
for 128weeks. Results showed that vitamin D increases were
associated with a decrease in disease activity and proteinuria
(64). Also, Abou-Raya et al. reported that lower vitamin D levels
correlated with disease activity and improvement in inflamma-
tory and hemostatic parameters was observed after 12months
treatment (71). Latest studies have found no association between
supplementation and disease activity and no changes in IFN sig-
nature in vitamin D deficient SLE patients (72, 73). Other studies
have shown effects in cytokine profiles and T cell differentia-
tion (74, 75).
A recent systematic review and meta-analyses of observational
and randomized trials (76) found no convincing evidence of a
clear role of vitamin D with highly significant results in both
randomized and observational studies. The number of random-
ized, controlled trials with vitamin D is scarce, so more data
are needed to reach a conclusion. Also, the effects of multiple
compounds when administered simultaneously, and the follow-
up time, may be inadequate to allow differences in disease occur-
rence. More efforts are required in order to clarify the role that
vitamin D has in this disease, to regulate the type of supplemen-
tation required, and to determine the minimal beneficial levels.
Specific attention to maintaining optimal vitamin D levels may be
beneficial in the management of SLE.
Conclusion
Vitamin D exerts important regulatory functions on cells from
the innate as well as from the adaptive immune response. Indeed,
accumulating evidence has shown that insufficient vitamin D
levels may lead to dysregulation of immune responses, and thus
contribute to autoimmune diseases. There is no consensus about
recommended targeted serum levels and the optimal mode and
dose of vitamin D supplementation. It seems that higher doses for
supplementation could have better outcomes in disease activity,
but still there is great variability between studies and no con-
clusions can be obtained. More and larger studies are needed to
determine how vitaminD supplementation affects the pathophys-
iology of SLE and how itmay contribute to better efficacy of actual
therapies.
Author Contributions
PB, RN, DH, and MI contributed to the design of this work,
drafting, and revising it critically. All authors gave their final
approval to the manuscript.
Funding
This work was funded by FONDECYT no. 1141211 (PB and
MI) and 1140049 (RN). DH is a CONICYT-PCHA/Doctorado
Nacional/2015-21150777 fellow.
References
1. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab (2010)
95(2):471–8. doi:10.1210/jc.2009-1773
2. Gröber U, Spitz J, Reichrath J, Kisters K, Holick MF. Vitamin D: update 2013:
from rickets prophylaxis to general preventive healthcare. Dermatoendocrinol
(2013) 5(3):331–47. doi:10.4161/derm.26738
3. Holick MF. Vitamin D deficiency. N Engl J Med (2007) 357(3):266–81. doi:10.
1056/NEJMra070553
4. Holick MF. Vitamin D: important for prevention of osteoporosis, cardio-
vascular heart disease, type 1 diabetes, autoimmune diseases, and some
cancers. South Med J (2005) 98(10):1024–7. doi:10.1097/01.SMJ.0000140865.
32054.DB
5. Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a
D-lightful story. J Bone Miner Res (2007) 22(Suppl 2):V28–33. doi:10.1359/
jbmr.07s211
6. Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits
and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc
Natl Acad Sci U S A (2008) 105(2):668–73. doi:10.1073/pnas.0710615105
7. Holick MF. Vitamin D: a millenium perspective. J Cell Biochem (2003)
88(2):296–307. doi:10.1002/jcb.10338
8. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function.
Nutrients (2013) 5(7):2502–21. doi:10.3390/nu5072502
9. DeLuca HF. Overview of general physiologic features and functions of vitamin
D. Am J Clin Nutr (2004) 80(6 Suppl):1689S–96S.
10. Carlberg C, CampbellMJ. VitaminD receptor signalingmechanisms: integrated
actions of a well-defined transcription factor. Steroids (2013) 78(2):127–36.
doi:10.1016/j.steroids.2012.10.019
11. Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vita-
min D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol
(2013) 45(2):217–26. doi:10.1007/s12016-013-8361-3
12. Rosen CJ, Gallagher JC. The 2011 IOM report on vitamin D and calcium
requirements for North America: clinical implications for providers treating
patients with low bone mineral density. J Clin Densitom (2011) 14(2):79–84.
doi:10.1016/j.jocd.2011.03.004
13. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The
2011 report on dietary reference intakes for calcium and vitamin D from the
Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab
(2011) 96(1):53–8. doi:10.1210/jc.2010-2704
14. Kongsbak M, von Essen MR, Levring TB, Schjerling P, Woetmann A, ØdumN,
et al. Vitamin D-binding protein controls T cell responses to vitamin D. BMC
Immunol (2014) 15:35. doi:10.1186/s12865-014-0035-2
Frontiers in Immunology | www.frontiersin.org October 2015 | Volume 6 | Article 5135
Iruretagoyena et al. Vitamin D and systemic lupus erythematosus
15. Safadi FF, Hermey DC, Popoff SN, Seifert MF. Skeletal resistance to 1,25-
dihydroxyvitamin D3 in osteopetrotic rats. Endocrine (1999) 11(3):309–19.
doi:10.1385/ENDO:11:3:309
16. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence
of vitamin D inadequacy among postmenopausal North American women
receiving osteoporosis therapy. J Clin Endocrinol Metab (2005) 90(6):3215–24.
doi:10.1210/jc.2004-2364
17. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailabil-
ity of vitamin D in obesity. Am J Clin Nutr (2000) 72(3):690–3.
18. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol
(2005) 289(1):F8–28. doi:10.1152/ajprenal.00336.2004
19. Grey A, Lucas J, Horne A, Gamble G, Davidson JS, Reid IR. Vitamin D reple-
tion in patients with primary hyperparathyroidism and coexistent vitamin D
insufficiency. J Clin Endocrinol Metab (2005) 90(4):2122–6. doi:10.1210/jc.
2004-1772
20. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B, Hathcock J, Giovannucci E,
Willett WC. Benefit-risk assessment of vitamin D supplementation. Osteoporos
Int (2010) 21(7):1121–32. doi:10.1007/s00198-009-1119-3
21. Bolland MJ, Bacon CJ, Horne AM, Mason BH, Ames RW, Wang TK, et al.
Vitamin D insufficiency and health outcomes over 5 y in older women. Am J
Clin Nutr (2010) 91(1):82–9. doi:10.3945/ajcn.2009.28424
22. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements
with or without vitamin D and risk of cardiovascular events: reanalysis of the
women’s health initiative limited access dataset and meta-analysis. BMJ (2011)
342:d2040. doi:10.1136/bmj.d2040
23. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, et al.
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity
and cancer: recommendations for clinical practice. Autoimmun Rev (2010)
9(11):709–15. doi:10.1016/j.autrev.2010.06.009
24. Lagishetty V, Misharin AV, Liu NQ, Lisse TS, Chun RF, Ouyang Y, et al. Vitamin
D deficiency in mice impairs colonic antibacterial activity and predisposes to
colitis. Endocrinology (2010) 151(6):2423–32. doi:10.1210/en.2010-0089
25. Grad R. Cod and the consumptive: a brief history of cod-liver oil in the
treatment of pulmonary tuberculosis. Pharm Hist (2004) 46(3):106–20.
26. Scherberich JE, Kellermeyer M, Ried C, Hartinger A. 1-Alpha-calcidol modu-
lates major human monocyte antigens and toll-like receptors TLR 2 and TLR4
in vitro. Eur J Med Res (2005) 10(4):179–82.
27. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu
Rev Immunol (2012) 30:1–22. doi:10.1146/annurev-immunol-100311-102839
28. Iruretagoyena MI, Wiesendanger M, Kalergis AM. The dendritic cell-T cell
synapse as a determinant of autoimmune pathogenesis. Curr Pharm Des (2006)
12(2):131–47. doi:10.2174/138161206775193145
29. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W. Regulatory dendritic
cells for immunotherapy in immunologic diseases. Front Immunol (2014) 5:7.
doi:10.3389/fimmu.2014.00007
30. Adorini L, Amuchastegui S, Corsiero E, Laverny G, Le Meur T, Penna G.
Vitamin D receptor agonists as anti-inflammatory agents. Expert Rev Clin
Immunol (2007) 3(4):477–89. doi:10.1586/1744666X.3.4.477
31. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic
cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin
D receptor-dependent pathway that promotes a persistent state of immaturity
in vitro and in vivo. ProcNatl Acad Sci U SA (2001) 98(12):6800–5. doi:10.1073/
pnas.121172198
32. Penna G, Amuchastegui S, Laverny G, Adorini L. Vitamin D receptor agonists
in the treatment of autoimmune diseases: selective targeting of myeloid but
not plasmacytoid dendritic cells. J Bone Miner Res (2007) 22(Suppl 2):V69–73.
doi:10.1359/jbmr.07s217
33. Rigby WF, Waugh M, Graziano RF. Regulation of human monocyte
HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-
dihydroxyvitamin D3. Blood (1990) 76(1):189–97.
34. Rolf L, Muris AH, Hupperts R, Damoiseaux J. Vitamin D effects on B cell
function in autoimmunity. Ann N Y Acad Sci (2014) 1317:84–91. doi:10.1111/
nyas.12440
35. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of
1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol (2007)
179(3):1634–47. doi:10.4049/jimmunol.179.3.1634
36. Hayes CE, Hubler SL, Moore JR, Barta LE, Praska CE, Nashold FE. Vitamin D
actions on CD4(+) T cells in autoimmune disease. Front Immunol (2015) 6:100.
doi:10.3389/fimmu.2015.00100
37. Croker JA, Kimberly RP. SLE: challenges and candidates in human disease.
Trends Immunol (2005) 26(11):580–6. doi:10.1016/j.it.2005.09.001
38. Hahn BH. Antibodies to DNA. N Engl J Med (1998) 338(19):1359–68. doi:10.
1056/NEJM199805073381906
39. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the
expression of experimental murine lupus of MRL/l mice. Autoimmunity (1992)
12(2):143–8. doi:10.3109/08916939209150321
40. Vaisberg MW, Kaneno R, Franco MF, Mendes NF. Influence of cholecalciferol
(vitamin D3) on the course of experimental systemic lupus erythematosus in
F1 (NZBxW)mice. J Clin Lab Anal (2000) 14(3):91–6. doi:10.1002/(SICI)1098-
2825(2000)14:3<91::AID-JCLA2>3.0.CO;2-O
41. Linker-Israeli M, Elstner E, Klinenberg JR, Wallace DJ, Koeffler HP. Vitamin
D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin
production by SLE-derived PBMC. Clin Immunol (2001) 99(1):82–93. doi:10.
1006/clim.2000.4998
42. Lerman M, Burnham J, Behrens E. 1,25 Dihydroxyvitamin D3 limits mono-
cyte maturation in lupus sera. Lupus (2011) 20(7):749–53. doi:10.1177/
0961203310394542
43. Ben-Zvi I, AranowC,MackayM, Stanevsky A, KamenDL,Marinescu LM, et al.
The impact of vitamin D on dendritic cell function in patients with systemic
lupus erythematosus. PLoS One (2010) 5(2):e9193. doi:10.1371/journal.pone.
0009193
44. WangG, Tam LS, Kwan BC, Li EK, ChowKM, Luk CC, et al. Expression ofmiR-
146a and miR-155 in the urinary sediment of systemic lupus erythematosus.
Clin Rheumatol (2012) 31(3):435–40. doi:10.1007/s10067-011-1857-4
45. de Azevêdo Silva J, Monteiro Fernandes K, Trés Pancotto JA, Sotero Fragoso T,
Donadi EA, Crovella S, et al. Vitamin D receptor (VDR) gene polymorphisms
and susceptibility to systemic lupus erythematosus clinical manifestations.
Lupus (2013) 22(11):1110–7. doi:10.1177/0961203313500549
46. Carvalho C, Marinho A, Leal B, Bettencourt A, Boleixa D, Almeida I, et al.
Association between vitamin D receptor (VDR) gene polymorphisms and sys-
temic lupus erythematosus in Portuguese patients. Lupus (2015) 24(8):846–53.
doi:10.1177/0961203314566636
47. Mao S,Huang S. Association between vitaminD receptor gene BsmI, FokI, ApaI
and TaqI polymorphisms and the risk of systemic lupus erythematosus: a meta-
analysis. Rheumatol Int (2014) 34(3):381–8. doi:10.1007/s00296-013-2898-6
48. Xiong J, He Z, Zeng X, Zhang Y, Hu Z. Association of vitamin D receptor gene
polymorphisms with systemic lupus erythematosus: a meta-analysis. Clin Exp
Rheumatol (2014) 32(2):174–81.
49. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C.
Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors
and clinical consequences. Rheumatology (Oxford) (2008) 47(6):920–3. doi:10.
1093/rheumatology/ken121
50. Yap KS, Morand EF. Vitamin D and systemic lupus erythematosus: continued
evolution. Int J Rheum Dis (2015) 18(2):242–9. doi:10.1111/1756-185X.12489
51. Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC,
et al. VitaminDdeficiency is associatedwith an increased autoimmune response
in healthy individuals and in patients with systemic lupus erythematosus. Ann
Rheum Dis (2011) 70(9):1569–74. doi:10.1136/ard.2010.148494
52. Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM. Hypovitaminosis
D is associated with greater body mass index and disease activity in pediatric
systemic lupus erythematosus. J Pediatr (2009) 155(2):260–5. doi:10.1016/j.
jpeds.2009.02.033
53. Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS.
Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev (2006)
5(2):114–7. doi:10.1016/j.autrev.2005.05.009
54. Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW, et al. Vita-
min D levels in women with systemic lupus erythematosus and fibromyalgia.
J Rheumatol (2001) 28(11):2535–9.
55. Mok CC. Vitamin D and systemic lupus erythematosus: an update. Expert Rev
Clin Immunol (2013) 9(5):453–63. doi:10.1586/eci.13.19
56. Costenbader KH, Feskanich D, Holmes M, Karlson EW, Benito-Garcia E.
Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid
arthritis in women. Ann Rheum Dis (2008) 67(4):530–5. doi:10.1136/ard.2007.
072736
57. Hiraki LT,Munger KL, Costenbader KH, Karlson EW.Dietary intake of vitamin
D during adolescence and risk of adult-onset systemic lupus erythematosus
and rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 64(12):1829–36.
doi:10.1002/acr.21776
Frontiers in Immunology | www.frontiersin.org October 2015 | Volume 6 | Article 5136
Iruretagoyena et al. Vitamin D and systemic lupus erythematosus
58. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH. Vitamin
D deficiency as marker for disease activity and damage in systemic lupus
erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus (2012)
21(1):36–42. doi:10.1177/0961203311422094
59. Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin
D levels in Chinese patients with systemic lupus erythematosus: relationship
with disease activity, vascular risk factors and atherosclerosis. Rheumatology
(Oxford) (2012) 51(4):644–52. doi:10.1093/rheumatology/ker212
60. Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, et al. 25-
Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus
erythematosus: data from a large international inception cohort. Arthritis Care
Res (Hoboken) (2014) 66(8):1167–76. doi:10.1002/acr.22291
61. Mandal M, Tripathy R, Panda AK, Pattanaik SS, Dakua S, Pradhan AK, et al.
Vitamin D levels in Indian systemic lupus erythematosus patients: association
with disease activity index and interferon alpha. Arthritis Res Ther (2014)
16(1):R49. doi:10.1186/ar4479
62. Schoindre Y, Jallouli M, Tanguy ML, Ghillani P, Galicier L, Aumaître O, et al.
Lower vitamin D levels are associated with higher systemic lupus erythe-
matosus activity, but not predictive of disease flare-up. Lupus Sci Med (2014)
1(1):e000027. doi:10.1136/lupus-2014-000027
63. Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E,
McCauliffe D, et al. Vitamin D status in systemic lupus erythematosus patients
and its association with selected clinical and laboratory parameters. Lupus
(2012) 21(5):477–84. doi:10.1177/0961203311427549
64. Petri M, Bello KJ, Fang H,Magder LS. Vitamin D in systemic lupus erythemato-
sus: modest association with disease activity and urine protein/creatinine ratio.
Arthritis Rheum (2013) 65(7):1865–71. doi:10.1002/art.37953
65. Reynolds JA, Haque S, Berry JL, Pemberton P, Teh LS, Ho P, et al. 25-
Hydroxyvitamin D deficiency is associated with increased aortic stiffness in
patients with systemic lupus erythematosus. Rheumatology (Oxford) (2012)
51(3):544–51. doi:10.1093/rheumatology/ker352
66. Toloza SM, Cole DE, Gladman DD, Ibañez D, Urowitz MB. Vitamin D insuf-
ficiency in a large female SLE cohort. Lupus (2010) 19(1):13–9. doi:10.1177/
0961203309345775
67. Souto M, Coelho A, Guo C, Mendonça L, Argolo S, Papi J, et al. Vitamin
D insufficiency in Brazilian patients with SLE: prevalence, associated fac-
tors, and relationship with activity. Lupus (2011) 20(10):1019–26. doi:10.1177/
0961203311401457
68. Stockton KA, Kandiah DA, Paratz JD, Bennell KL. Fatigue, muscle strength and
vitamin D status in women with systemic lupus erythematosus compared with
healthy controls. Lupus (2012) 21(3):271–8. doi:10.1177/0961203311425530
69. Schneider L, Colar da Silva AC, Werres Junior LC, Alegretti AP, Dos San-
tos AS, Santos M, et al. Vitamin D levels and cytokine profiles in patients
with systemic lupus erythematosus. Lupus (2015) 24(11):1191–7. doi:10.1177/
0961203315584811
70. Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes
in vitamin D levels in patients with systemic lupus erythematosus: effects
on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken) (2010)
62(8):1160–5. doi:10.1002/acr.20186
71. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementa-
tion on inflammatory and hemostatic markers and disease activity in patients
with systemic lupus erythematosus: a randomized placebo-controlled trial. J
Rheumatol (2013) 40(3):265–72. doi:10.3899/jrheum.111594
72. Andreoli L, Dall’Ara F, Piantoni S, Zanola A, Piva N, Cutolo M, et al. A 24-
month prospective study on the efficacy and safety of two different monthly
regimens of vitamin D supplementation in pre-menopausal women with
systemic lupus erythematosus. Lupus (2015) 24(4–5):499–506. doi:10.1177/
0961203314559089
73. Aranow C, Kamen DL, Dall’Era M, Massarotti EM, Mackay MC, Koumpouras
F, et al. Randomized, double-blind, placebo-controlled trial of the effect of
vitamin D3 on the interferon signature in patients with systemic lupus erythe-
matosus. Arthritis Rheumatol (2015) 67(7):1848–57. doi:10.1002/art.39108
74. Piantoni S, Andreoli L, Scarsi M, Zanola A, Dall’Ara F, Pizzorni C, et al.
Phenotype modifications of T-cells and their shift toward a Th2 response
in patients with systemic lupus erythematosus supplemented with different
monthly regimens of vitamin D. Lupus (2015) 24(4–5):490–8. doi:10.1177/
0961203314559090
75. Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, et al. Restoration
of regulatory and effector T cell balance andB cell homeostasis in systemic lupus
erythematosus patients through vitamin D supplementation. Arthritis Res Ther
(2012) 14(5):R221. doi:10.1186/ar4060
76. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple
health outcomes: umbrella review of systematic reviews and meta-analyses of
observational studies and randomised trials. BMJ (2014) 348:g2035. doi:10.
1136/bmj.g2035
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Iruretagoyena, Hirigoyen, Naves and Burgos. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | www.frontiersin.org October 2015 | Volume 6 | Article 5137
